Lower Drug Dose Spells Trouble For Pharmacogenetic Test
This article was originally published in The Gray Sheet
Executive Summary
A study published in the June 20 issue of the Journal of Clinical Oncology shows that a genetic test is unnecessary in children if the cancer drug irinotecan is given in a low dose over a period of days
You may also be interested in...
FDA Clears Third Wave Invader Pharmacogenetic Test
Oncologists will be able to use Third Wave Technologies' Invader UGT1A1 molecular assay to select appropriate doses of Pfizer's chemotherapy drug Camptosar (irinotecan)for colorectal cancer, following 510(k) clearance Aug. 22
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.